Scythian Biosciences

Concussion-focused Scythian sets market debut

By GREGORY ZELLER // Scythian Biosciences Corp. is going public. The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets. Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of…


Feinstein, Hofstra concussion study exposes a nerve

By GREGORY ZELLER // With concussions and other traumatic brain injuries continuing to make headlines on and off the playing field, Long Island researchers may be closing in on a unique treatment method. Scientists at the Feinstein Institute for Medical Research and the Hofstra Northwell School of Medicine have published the results of a nerve-stimulation study with broad-ranging implications for many neurological conditions, including severe TBIs. Published online by the international science journal Nature, the…


Financing set, cannabinoid-concussion study aims high

By GREGORY ZELLER // And now, onto the science. Canadian mining exploration company Kitrinor Metals Inc. and Scythian Biosciences Inc., a Calgary-based biotech owned by Great Neck investment banker Jonathan Gilbert, have announced a pair of deals that complete first-round financing for Scythian, which is exploring cannabinoid-based treatments for concussions. The new deals add on to the $13.08 million (Canadian) in brokered financing, led by Ontario-based Clarus Securities Inc., already raised by Scythian Biosciences, which…


Stock deal locks funds for Scythian marijuana study

By GREGORY ZELLER // A Canadian R&D firm with Long Island roots has locked up the first tranche of a strategic investment that will fund a major study involving concussions and medical marijuana. Scythian Biosciences Inc. and Canadian mining exploration company Kitrinor Metals Inc. on Tuesday announced a “brokered private placement” that gives 32.7 million common shares of Calgary-based Scythian, owned by Great Neck investment banker Jonathan Gilbert, to an investment team including lead agent…


Scythian, U of M concussion study hits the jack-pot

By GREGORY ZELLER // A Calgary-based R&D firm with strong Long Island ties has swung an eight-figure financing deal, lighting up a major study pitting cannabinoids against concussions. Scythian Biosciences Inc. – owned by owned by Great Neck investment banker Jonathan Gilbert, who partners in fitness-nutrition enterprise Decision Nutrition with his wife, Keren Gilbert, among other ventures – and the University of Miami stand ready with a planned five-year, $16 million study of cannabinoid-based methods…


Tackling concussions with cannabis

By GREGORY ZELLER // A research effort stretching from Florida to Long Island to Canada’s Alberta province will determine if compounds derived from marijuana can be effective treatments for concussions. Calgary-based R&D firm Scythian Biosciences has agreed to fund a University of Miami study, to be conducted by the university’s The Miami Project to Cure Paralysis and Miller School of Medicine, exploring cannabinoid-based methods of reducing post-concussion brain cell inflammation, which causes headaches and other neurological complications….